Donepezil Hydrochloride Tablet, Film Coated
Product Images NDC 62332-092

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Donepezil Hydrochloride (NDC 62332-092). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Alembic Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Donepezil 10 mg

Donepezil Hydrochloride 10 mg film-coated tablets label. The label indicates the product is manufactured by Alembic Pharmaceuticals Inc. It includes dosage and storage information, stating the tablets are to be stored at 20° to 25°C. The package contains 30 tablets and is labeled for Rx only. The label also features a barcode and a note directing pharmacists to dispense the patient information sheet.*

FDA Label Image

Donepezil Figur11

A line graph illustrating the change from baseline in SIB (Severe Impairment Battery) scores over 24 weeks of treatment with Donepezil Hydrochloride at doses of 10 mg/day and 23 mg/day. The vertical axis shows SIB change with clinical improvement and decline indicated, while the horizontal axis shows weeks of drug treatment. The 23 mg/day dose shows greater improvement than the 10 mg/day dose over time, with error bars representing the standard error.*

FDA Label Image

Donepezil Figur12

A cumulative percentage of patients chart comparing SIB change from baseline for Donepezil Hydrochloride at doses of 10 mg/day and 23 mg/day. The x-axis shows SIB change from baseline, and the y-axis shows the cumulative percentage of patients. Data points are plotted with distinct markers for each dose.*

FDA Label Image

Donepezil Figur13

A bar graph comparing the percentage of patients with different CIBIC-plus ratings after treatment with Donepezil Hydrochloride 23 mg/day and 10 mg/day. The ratings include Markedly Improved, Moderately Improved, Minimally Improved, No Change, Minimally Worse, Moderately Worse, and Markedly Worse, showing patient response distribution at these dosages.*

FDA Label Image

Figure 1 (Donepezil Figure1)

A line graph illustrating the time-course of change from baseline in ADAS-cog scores over 24 weeks of treatment with Donepezil Hydrochloride at 10 mg/day, 5 mg/day, and placebo. The vertical axis represents mean change from baseline, with clinical improvement and decline indicated. The horizontal axis is weeks of drug treatment up to 24 weeks, plus a placebo control.*

FDA Label Image

Figure 10 (Donepezil Figure10)

A cumulative percentage curve graph displaying patients completing 6 months of double-blind treatment with Donepezil Hydrochloride 10 mg/day versus placebo. The x-axis shows ADCS-ADL change from baseline scores, while the y-axis shows the cumulative percentage of patients, illustrating treatment effects on ADCS-ADL-Severe scores.*

FDA Label Image

Figure 2 (Donepezil Figure2)

A cumulative percentage figure showing changes from baseline in ADAS-cog scores over 24 weeks for patients treated with placebo and Donepezil Hydrochloride tablets at 5 mg and 10 mg doses. The graph plots cumulative percentages of patients against change scores, indicating treatment group response rates at various change points.*

FDA Label Image

Figure 3 (Donepezil Figure3)

Bar chart depicting the frequency distribution of CIBIC-plus scores at Week 24 for Donepezil hydrochloride 10 mg/day, 5 mg/day, and placebo groups. The x-axis shows categories from Markedly Improved to Markedly Worse, and the y-axis represents the percentage of patients in each category.*

FDA Label Image

Figure 4 (Donepezil Figure4)

A line chart showing changes from baseline in ADAS-cog scores over 15 weeks for patients using Donepezil hydrochloride 10 mg/day, 5 mg/day, and placebo. The y-axis represents the mean change from baseline with error bars. The x-axis shows weeks of drug treatment, highlighting trends in clinical improvement or decline among the three groups.*

FDA Label Image

Figure 5 (Donepezil Figure5)

A line graph displaying the cumulative percentage of patients with specified changes from baseline ADAS-cog scores. The graph compares three treatment groups: placebo, Donepezil hydrochloride 5 mg, and Donepezil hydrochloride 10 mg, with change from baseline on the x-axis and cumulative percentage of patients on the y-axis. Vertical lines indicate 7 points, 4 points, and no change milestones.*

FDA Label Image

Figure 6 (Donepezil Figure6)

A bar chart showing the frequency distribution of CIBIC-plus scores at week 12 among patients treated with Donepezil hydrochloride 10 mg/day, 5 mg/day, and placebo. The chart categorizes patient outcomes by levels of improvement or worsening, including markedly improved, moderately improved, minimally improved, no change, minimally worse, moderately worse, and markedly worse, with percentages on the vertical axis.*

FDA Label Image

Figure 7 (Donepezil Figure7)

A line graph depicting the time course of change from baseline in SIB (Severe Impairment Battery) score for patients treated with Donepezil Hydrochloride 10 mg/day compared to placebo over 6 months. The y-axis shows mean change from baseline with standard error (SE), indicating clinical improvement or decline, while the x-axis represents months of drug treatment.*

FDA Label Image

Figure 8 (Donepezil Figure8)

A cumulative percentage graph showing patients completing 6 months of double-blind treatment with Donepezil Hydrochloride 10 mg/day versus placebo. The x-axis represents the change from baseline in SIB scores, while the y-axis shows the cumulative percentage of patients. Donepezil group data points are marked with solid circles, placebo with open squares.*

FDA Label Image

Donepezil mg5

Donepezil Hydrochloride Tablets, USP 5 mg film-coated tablets in a 30-tablet package by Alembic Pharmaceuticals Inc. The label includes dosage information, storage instructions, barcode, and prescription only (Rx only) designation.*

FDA Label Image

Structure (Donepezil Structure)

Chemical structure of Donepezil Hydrochloride, illustrating its molecular arrangement including the methoxy-substituted aromatic ring, a piperidine ring, and a benzyl group linked to hydrochloride.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.